Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Simulations PlusSLP +0.14%83 EV-to-EBITDA is 18.67 as of Jul. 15, 2026, which is 59% below its 10-year median of 45.35. GuruFocus rates SLP with a GF Score™ of 83/100 and a GF Value™ of $35.40 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 507 Healthcare Providers & Services companies, Simulations Plus ranks worse than 73.77% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Simulations Plus's enterprise value is $319.50 Mil.
Simulations Plus's EBITDA for the trailing twelve months (TTM) ended in May. 2026 was $17.12 Mil. Therefore, Simulations Plus's EV-to-EBITDA for today is 18.67.
The historical rank and industry rank for Simulations Plus's EV-to-EBITDA or its related term are showing as below:
SLP'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 11.46 Med: 45.35 Max: 111.68
Current: 18.67
During the past 13 years, the highest EV-to-EBITDA of Simulations Plus was 111.68. The lowest was 11.46. And the median was 45.35.
SLP's EV-to-EBITDA is ranked worse than 73.77% of 507
companies
in the Healthcare Providers & Services industry
Industry Median: 10.89
vs SLP: 18.67
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Simulations Plus (NAS:SLP) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Simulations Plus's PE Ratio (TTM) for today is calculated as:
Simulations Plus's share price for today is $18.245.
Simulations Plus's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.400.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Simulations Plus's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Simulations Plus's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Simulations Plus EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Simulations Plus's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Simulations Plus's EV-to-EBITDA falls into.
Simulations Plus's current Enterprise Value is $319.50 Mil.
Simulations Plus's EBITDA for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $17.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simulations Plus (SLP) has a EV-to-EBITDA of 18.67 as of Jul. 15, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Simulations Plus. This is 59% below median its historical median of 45.35. Over the past decade, Simulations Plus' EV-to-EBITDA has ranged from 11.46 to 111.68. According to the industry distribution chart, Simulations Plus ranks #374 out of 507 companies in the Healthcare Providers & Services industry, placing it in the top 73.8%.
Is Simulations Plus' EV-to-EBITDA too high?
Simulations Plus' current EV-to-EBITDA of 18.67 is 59% below median its 10-year median of 45.35. Over the past 10 years, this metric has ranged from a low of 11.46 to a high of 111.68. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.89. Simulations Plus' value of 18.67 is 71.4% above this industry median. Based on the distribution chart, Simulations Plus ranks #374 out of 507 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Simulations Plus has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Simulations Plus' EV-to-EBITDA compare to TBRG and CARL?
According to the Healthcare Providers & Services industry distribution chart, Simulations Plus ranks #374 out of 507 companies for EV-to-EBITDA. This places Simulations Plus in the lower half of its industry. The industry median EV-to-EBITDA is 10.89. Simulations Plus' value of 18.67 is 71.4% above this benchmark. Historically, Simulations Plus' own EV-to-EBITDA has ranged from 11.46 to 111.68 over the past decade. While the company's 10-year median is 45.35 vs. the industry median of 10.89, Simulations Plus has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.89, based on 507 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Simulations Plus's current EV-to-EBITDA of 18.67 is 71.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Simulations Plus. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Simulations Plus's current EV-to-EBITDA is 18.67, which is 59% below median its own 10-year median of 45.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simulations Plus stock overvalued right now?
Based on GuruFocus' analysis, Simulations Plus (SLP) is currently considered Significantly Undervalued. The stock's GF Value™ is $35.40, compared to a current price of $18.25 — trading 48.5% below its estimated fair value. The current EV-to-EBITDA is 18.67, which is 59% below median its 10-year median of 45.35 and 71.4% above the Healthcare Providers & Services industry median of 10.89. Simulations Plus' overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Simulations Plus (SLP), the current EV-to-EBITDA is 18.67 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Simulations Plus (SLP) Overvalued in 2026?
Based on GuruFocus' analysis, Simulations Plus stock appears to be undervalued.
The current stock price of $18.25 is trading 48.5% below its estimated GF Value™ of $35.40.
GuruFocus considers Simulations Plus to be Significantly Undervalued.
Key valuation signals for SLP:
EV-to-EBITDA: 18.67 (59% below median its 10-year median of 45.35)
GF Value™: $35.40 vs. price of $18.25 (48.5% below fair value)
Industry Position: 71.4% above the Healthcare Providers & Services median (#374 of 507)
No single metric tells the full story. See the SLP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
83GF Score
Get the complete analysis for SLP
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLP has been successfully added to your 
